Mesenchymal stem cells for the treatment of immune-mediated diseases

Liau, Ling Ling; Looi, Qi Hao; Eng, Sue Ping; Yazid, Muhammad Dain; Sulaiman, Nadiah; Busra, Mohd Fauzi Mh; Ng, Min Hwei; Law, Jia Xian

doi:10.1142/9789811205538_0007

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Standardization and commercialization of allogeneic MSCs would be readily available at a reduced cost due to the lack of need to create a personalized cell therapy from the autologous source and the potential of expanding the cells in large-scale [ 142 ]. To date, MSCs have been used in clinical trials for osteoarthritis, spinal cord injury, diabetes mellitus, autoimmune disease (Crohn’s disease, multiple sclerosis, systemic lupus erythematosus, and systemic sclerosis), and systemic diseases such as graft-versus-host diseases and sepsis [ 30 , 143 , 144 , 145 ]. Additionally, MSCs also have been used to treat neonatal diseases, i.e., intraventricular hemorrhage, bronchopulmonary dysplasia, and necrotizing enterocolitis [ 146 ].…”

Section: Mesenchymal Stem Cell Therapy To Reverse Aging Effects On the Immune Systemmentioning

confidence: 99%

Potential of Mesenchymal Stem Cells in the Rejuvenation of the Aging Immune System

Yeo

Nordin

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Rapid growth of the geriatric population has been made possible with advancements in pharmaceutical and health sciences. Hence, age-associated diseases are becoming more common. Aging encompasses deterioration of the immune system, known as immunosenescence. Dysregulation of the immune cell production, differentiation, and functioning lead to a chronic subclinical inflammatory state termed inflammaging. The hallmarks of the aging immune system are decreased naïve cells, increased memory cells, and increased serum levels of pro-inflammatory cytokines. Mesenchymal stem cell (MSC) transplantation is a promising solution to halt immunosenescence as the cells have excellent immunomodulatory functions and low immunogenicity. This review compiles the present knowledge of the causes and changes of the aging immune system and the potential of MSC transplantation as a regenerative therapy for immunosenescence.

show abstract

Section: Mesenchymal Stem Cell Therapy To Reverse Aging Effects On the Immune Systemmentioning

confidence: 99%

Potential of Mesenchymal Stem Cells in the Rejuvenation of the Aging Immune System

Yeo

Nordin

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Serum TNF-α, C-reactive protein (CRP) and interleukin (IL)-6 are inflammatory markers that are consistently linked with age-related chronic diseases [ 5 ]. Numerous studies have reported that MSCs are able to modulate the activities of immune cells which subsequently alter the cytokine secretion [ 14 , 15 , 16 ]. In addition, MSCs also have been demonstrated to be beneficial in ameliorating degenerative diseases such as cardiovascular disease [ 17 , 18 ], osteoarthritis [ 19 , 20 ], muscular dystrophy [ 21 ], and neurodegenerative diseases such as multiple sclerosis [ 22 ].…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal Stem Cell Transplantation for the Treatment of Age-Related Musculoskeletal Frailty

Mahindran

Law

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Projected life expectancy continues to grow worldwide owing to the advancement of new treatments and technologies leading to rapid growth of geriatric population. Thus, age-associated diseases especially in the musculoskeletal system are becoming more common. Loss of bone (osteoporosis) and muscle (sarcopenia) mass are conditions whose prevalence is increasing because of the change in population distribution in the world towards an older mean age. The deterioration in the bone and muscle functions can cause severe disability and seriously affects the patients’ quality of life. Currently, there is no treatment to prevent and reverse age-related musculoskeletal frailty. Existing interventions are mainly to slow down and control the signs and symptoms. Mesenchymal stem cell (MSC) transplantation is a promising approach to attenuate age-related musculoskeletal frailty. This review compiles the present knowledge of the causes and changes of the musculoskeletal frailty and the potential of MSC transplantation as a regenerative therapy for age-related musculoskeletal frailty.

show abstract

“…Regardless of the tissue sources, MSCs have low immunogenicity and can suppress the activation of immune cells ( 10 ). Therefore, both autologous and allogeneic MSCs can be used clinically as the cells have a very low risk of being rejected by the host immune system.…”

Section: Introductionmentioning

confidence: 99%

The Potential of Mesenchymal Stromal Cell as Therapy in Neonatal Diseases

et al. 2020

Self Cite

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) can be derived from various tissue sources, such as the bone marrow (BMSCs), adipose tissue (ADSCs), umbilical cord (UC-MSCs) and umbilical cord blood (UCB-MSCs). Clinical trials have been conducted to investigate the potential of MSCs in ameliorating neonatal diseases, including bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH) and necrotizing enterocolitis (NEC). In preclinical studies, MSC therapy has been tested for the treatment of various neonatal diseases affecting the heart, eye, gut, and brain as well as sepsis. Up to date, the number of clinical trials using MSCs to treat neonatal diseases is still limited. The data reported thus far positioned MSC therapy as safe with positive outcomes. However, most of these trials are still preliminary and generally smaller in scale. Larger trials with more appropriate controls and a longer follow-up period need to be conducted to prove the safety and efficacy of the therapy more conclusively. This review discusses the current application of MSCs in treating neonatal diseases, its mechanism of action and future direction of this novel therapy, including the potential of using MSC-derived extracellular vesicles instead of the cells to treat various clinical conditions in the newborn.

show abstract

Mesenchymal stem cells for the treatment of immune-mediated diseases

Cited by 6 publications

References 0 publications

Potential of Mesenchymal Stem Cells in the Rejuvenation of the Aging Immune System

Potential of Mesenchymal Stem Cells in the Rejuvenation of the Aging Immune System

Mesenchymal Stem Cell Transplantation for the Treatment of Age-Related Musculoskeletal Frailty

The Potential of Mesenchymal Stromal Cell as Therapy in Neonatal Diseases

Contact Info

Product

Resources

About